HK1055389A1 - Analgesic compositions containing buprenorphine - Google Patents

Analgesic compositions containing buprenorphine

Info

Publication number
HK1055389A1
HK1055389A1 HK03107582.6A HK03107582A HK1055389A1 HK 1055389 A1 HK1055389 A1 HK 1055389A1 HK 03107582 A HK03107582 A HK 03107582A HK 1055389 A1 HK1055389 A1 HK 1055389A1
Authority
HK
Hong Kong
Prior art keywords
compositions containing
containing buprenorphine
analgesic compositions
analgesic
buprenorphine
Prior art date
Application number
HK03107582.6A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Keith Mccormack
Nicolas Calvert Varey
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9927359.1A external-priority patent/GB9927359D0/en
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of HK1055389A1 publication Critical patent/HK1055389A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK03107582.6A 1999-11-19 2003-10-20 Analgesic compositions containing buprenorphine HK1055389A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9927359.1A GB9927359D0 (en) 1999-11-19 1999-11-19 Improvements in or relating to organic compositions
US17620800P 2000-01-14 2000-01-14
PCT/GB2000/004372 WO2001035942A2 (en) 1999-11-19 2000-11-17 Analgesic compositions containing buprenorphine

Publications (1)

Publication Number Publication Date
HK1055389A1 true HK1055389A1 (en) 2004-01-09

Family

ID=26316086

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03107582.6A HK1055389A1 (en) 1999-11-19 2003-10-20 Analgesic compositions containing buprenorphine

Country Status (31)

Country Link
US (4) US6995169B2 (hu)
EP (1) EP1242087B1 (hu)
JP (1) JP4745576B2 (hu)
KR (1) KR100726699B1 (hu)
CN (1) CN100431543C (hu)
AR (1) AR031682A1 (hu)
AT (1) ATE262335T1 (hu)
AU (1) AU777259B2 (hu)
BR (1) BR0015580A (hu)
CA (1) CA2392013C (hu)
CO (1) CO5261517A1 (hu)
CZ (1) CZ303160B6 (hu)
DE (1) DE60009346T2 (hu)
DK (1) DK1242087T3 (hu)
ES (1) ES2214334T3 (hu)
GB (1) GB2356348B (hu)
HK (1) HK1055389A1 (hu)
HU (1) HU229565B1 (hu)
IL (2) IL149580A0 (hu)
MX (1) MXPA02004978A (hu)
NO (1) NO321965B1 (hu)
NZ (1) NZ519023A (hu)
PL (1) PL199727B1 (hu)
PT (1) PT1242087E (hu)
RO (1) RO121174B1 (hu)
RU (1) RU2255737C2 (hu)
SI (1) SI21025B (hu)
SK (1) SK286888B6 (hu)
TR (1) TR200400653T4 (hu)
TW (1) TW550070B (hu)
WO (1) WO2001035942A2 (hu)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
SI2316456T1 (sl) 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
US8093261B2 (en) 2006-10-24 2012-01-10 The Johns Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
KR20160072276A (ko) * 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
GB2447015A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
KR101545874B1 (ko) * 2007-09-03 2015-08-20 나노테라퓨틱스, 인코포레이티드 난용성 약물의 전달을 위한 입상 조성물
US20090082383A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched buprenorphine
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
BR112012016783A2 (pt) * 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
CN104873455B (zh) 2010-12-22 2023-09-12 普渡制药公司 包覆的抗篡改控制释放剂型
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
KR102078044B1 (ko) 2011-09-19 2020-02-17 오렉쏘 에이비 오피오이드 의존증의 치료를 위한 남용-방지성 약학 조성물
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
WO2014120936A2 (en) 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ES2802976T3 (es) 2013-09-10 2021-01-22 Fresh Cut Dev Llc Pulverizador de buprenorfina sublingual
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3166250A1 (en) * 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8430109D0 (en) 1984-11-29 1985-01-09 Gkn Technology Ltd Securing components
GB8430346D0 (en) * 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
US20010006967A1 (en) * 1992-09-21 2001-07-05 Stanley M. Crain Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
AU2001259458B2 (en) * 2000-05-05 2006-09-14 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist compositions and dosage forms

Also Published As

Publication number Publication date
WO2001035942A9 (en) 2002-11-28
NZ519023A (en) 2004-11-26
NO20022330D0 (no) 2002-05-15
TW550070B (en) 2003-09-01
AU777259B2 (en) 2004-10-07
DK1242087T3 (da) 2004-07-19
WO2001035942A2 (en) 2001-05-25
CO5261517A1 (es) 2003-03-31
AR031682A1 (es) 2003-10-01
DE60009346D1 (de) 2004-04-29
RU2255737C2 (ru) 2005-07-10
GB2356348B (en) 2002-02-06
KR20020058022A (ko) 2002-07-12
WO2001035942A3 (en) 2002-06-13
GB0028088D0 (en) 2001-01-03
JP2003514013A (ja) 2003-04-15
PL199727B1 (pl) 2008-10-31
RU2002116361A (ru) 2004-01-27
CZ303160B6 (cs) 2012-05-09
RO121174B1 (ro) 2007-01-30
EP1242087A2 (en) 2002-09-25
MXPA02004978A (es) 2003-01-28
ATE262335T1 (de) 2004-04-15
NO20022330L (no) 2002-07-04
US20060058333A1 (en) 2006-03-16
BR0015580A (pt) 2002-07-09
PL355330A1 (en) 2004-04-19
US20060069113A1 (en) 2006-03-30
US20060058332A1 (en) 2006-03-16
NO321965B1 (no) 2006-07-31
TR200400653T4 (tr) 2004-04-21
ES2214334T3 (es) 2004-09-16
AU1529701A (en) 2001-05-30
CA2392013A1 (en) 2001-05-25
DE60009346T2 (de) 2005-02-10
US6995169B2 (en) 2006-02-07
SK286888B6 (sk) 2009-07-06
PT1242087E (pt) 2004-06-30
KR100726699B1 (ko) 2007-06-13
EP1242087B1 (en) 2004-03-24
CN1413110A (zh) 2003-04-23
HUP0203588A2 (hu) 2003-03-28
IL149580A (en) 2007-05-15
IL149580A0 (en) 2002-11-10
HUP0203588A3 (en) 2005-01-28
GB2356348A (en) 2001-05-23
US7402591B2 (en) 2008-07-22
JP4745576B2 (ja) 2011-08-10
HU229565B1 (hu) 2014-02-28
SI21025B (sl) 2008-04-30
SK8762002A3 (en) 2002-12-03
SI21025A (sl) 2003-04-30
US20030004178A1 (en) 2003-01-02
CN100431543C (zh) 2008-11-12
CA2392013C (en) 2009-08-11

Similar Documents

Publication Publication Date Title
IL149580A0 (en) Analgesic compositions containing buprenorphine
GB9902520D0 (en) Composition
AP2001002273A0 (en) Rescorcinol composition
GB9919683D0 (en) Composition
GB2366984B (en) Composition
GB9914446D0 (en) Composition
GB2357714B (en) Composition
HU9700801D0 (en) New analgesic compositions
GB9914582D0 (en) Composition
GB9912409D0 (en) Compounds and compositions
GB9906607D0 (en) Oral composition
GB9910167D0 (en) Composition
GB9914714D0 (en) Composition
GB9918591D0 (en) Composition
GB9926432D0 (en) Composition
GB9906689D0 (en) Composition
GB9906690D0 (en) Composition
GB9907146D0 (en) Composition
GB9907270D0 (en) Composition
GB9925711D0 (en) Composition
GB9911933D0 (en) Composition
GB9919953D0 (en) Composition
GB9915435D0 (en) Composition
GB9914596D0 (en) Composition
GB9914601D0 (en) Composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151117